血清miR-23a、miR-150、miR-150-5p水平与糖尿病性骨质疏松症的相关性

doi:10.3969/j.issn.1006-5725.2024.16.008

Abstract

Abstract:

Objective To investigate the association between microRNA （miR）?23a， miR?150， and miR?150?5p levels and diabetic osteoporosis（DOP） through correlation analysis. Methods A total of 200 patients with diabetes who visited the hospital between March 2020 and March 2022 were selected and followed up for a duration of 2 years. Patients who developed DOP and those who did not were respectively assigned to the DOP group and the non?DOP group. The general information and serum levels of miR?23a， miR?150， and miR?150?5p between these two groups were compared. Pearson correlation analysis was conducted to examine the relationship between serum levels of miR?23a， miR?150， and miR?150?5p， as well as bone density. Logistic regression model was employed to identify factors influencing DOP. Results The incidence rate of DOP was 28.89%. The serum levels of miR?23a， miR?150， and miR?150?5p were significantly elevated in the DOP group compared to the non?DOP group （P < 0.05）. Pearson correlation analysis revealed a negative association between the serum levels of miR?23a， miR?150， and miR?150?5p in diabetic patients and bone density （P < 0.05）. Logistic regression model analysis demonstrated that age， body mass index （BMI）， as well as miR?23a， miR?150， and miR?150?5p were influential factors contributing to the development of DOP （P < 0.05）. Conclusion The levels of serum miR?23a， miR?150， and miR?150?5p are elevated in patients with DOP， and all three exhibit a negative correlation with bone density. Furthermore， these factors collectively contribute to the development of DOP.

Key words: diabetes, osteoporosis, microRNA?23a, microRNA?150, microRNA?150?5p

CLC Number:

R587.1

Xiaoli SUN,Huijie. FAN. Correlation between serum levels of miR⁃23a， miR⁃150， and miR⁃150⁃5p and diabetic osteoporosis[J]. The Journal of Practical Medicine, 2024, 40(16): 2244-2249.

Figures/Tables 8

Tab.1

Tab.2

Comparison of general data between the two groups"

一般资料	DOP组（n = 52）	无DOP组（n = 128）	t/χ²/Z值	P值
年龄（x ± s，岁）	68.75 ± 9.16	64.32 ± 10.24	2.709	0.007
性别［例（%）］
男	25（48.08）	76（59.38）	1.917	0.166
女	27（51.92）	52（40.63）	1.917	0.166
BMI（x ± s，kg/m²）	23.09 ± 2.79	23.97 ± 2.53	2.053	0.042
吸烟［例（%）］
是	22（42.31）	46（35.94）	0.638	0.424
否	30（57.69）	82（64.06）	0.638	0.424
饮酒［例（%）］
是	23（44.23）	53（41.41）	0.121	0.728
否	29（55.77）	75（58.59）	0.121	0.728
文化程度［例（%）］
初中及以下	34（65.38）	66（51.56）	2.861	0.091
高中及以上	18（34.62）	62（48.44）	2.861	0.091
职业类型［例（%）］
体力型	19（36.54）	38（29.69）	0.828	0.661
脑力型	20（38.46）	56（43.75）
体力、脑力混合型	13（25.00）	34（26.56）
居住地［例（%）］
农村	35（67.31）	77（60.16）	0.805	0.370
城市	17（32.69）	51（39.84）	0.805	0.370
婚姻状况［例（%）］
已婚	32（61.54）	91（71.09）	1.560	0.212
未婚、离异、丧偶	20（38.46）	37（28.91）	1.560	0.212
高脂血症史［例（%）］
有	39（75.00）	86（67.19）	1.064	0.302
无	13（25.00）	42（32.81）	1.064	0.302
高血压史［例（%）］
有	38（73.08）	86（67.19）	0.598	0.439
无	14（26.92）	42（32.81）	0.598	0.439
每周运动时间［M（P₂₅，P₇₅），h］	4（0，6）	5（0，7）	1.819	0.071
遵医嘱补充钙剂［例（%）］
是	11（21.15）	44（34.38）	3.046	0.081
否	41（78.85）	84（65.63）	3.046	0.081
纯素食［例（%）］
是	5（9.62）	5（3.91）	2.297	0.130
否	47（90.38）	123（96.09）	2.297	0.130
糖尿病病程［M（P₂₅，P₇₅），年］	10（5，19）	8（4，17）	2.496	0.013
FPG（x ± s，mmol/L）	7.78 ± 2.23	7.03 ± 2.19	2.072	0.040
HbA_1c（x ± s，%）	6.99 ± 1.12	6.53 ± 1.04	2.630	0.009
Alb（x ± s，g/L）	32.63 ± 7.02	34.12 ± 7.13	1.276	0.203
TC（x ± s，mmol/L）	4.62 ± 0.91	4.77 ± 0.93	0.987	0.325
HDL-C（x ± s，mmol/L）	1.09 ± 0.24	1.11 ± 0.31	0.417	0.677
AST（x ± s，U/L）	37.41 ± 6.32	36.19 ± 6.44	1.158	0.248
BUA（x ± s，mmol/L）	422.63 ± 56.34	403.03 ± 61.56	1.983	0.049
Scr（x ± s，mg/dL）	1.70 ± 0.38	1.63 ± 0.49	0.923	0.357

Tab.2

Tab.3

Tab.4

Fig.1

Fig.2

Fig.3

Tab.5

References 20

1	KALRA S， JOSHI A， KAPOOR N. Osteoporosis and diabetes： The dual pandemics［J］. J Pak Med Assoc， 2022， 72（8）：1663-1664.
2	MCCONNELL M， SHIEH A. Polypharmacy in osteoporosis treatment［J］. Clin Geriatr Med， 2022， 38（4）：715-726. doi:10.1016/j.cger.2022.05.011 doi: 10.1016/j.cger.2022.05.011
3	DAAMOUCH S， EMINI L， RAUNER M， et al. MicroRNA and diabetic bone disease［J］. Curr Osteoporos Rep， 2022， 20（3）：194-201. doi:10.1007/s11914-022-00731-0 doi: 10.1007/s11914-022-00731-0
4	XU Y， JIANG Y， WANG Y， et al. LINC00473-modified bone marrow mesenchymal stem cells incorporated thermosensitive PLGA hydrogel transplantation for steroid-induced osteonecrosis of femoral head： A detailed mechanistic study and validity evaluation［J］. Bioeng Transl Med， 2021， 7（2）：e10275. doi:10.1002/btm2.10275 doi: 10.1002/btm2.10275
5	冯保静，赵西博，张伟祥. miR-150靶向β-catenin调控人牙周膜干细胞成骨分化能力的机制研究［J］. 中华老年口腔医学杂志， 2023， 21（3）：142-147.
6	LI Y， QI W， SHI Y. miR-150-5p inhibits osteogenic differentiation of fibroblasts in ankylosing spondylitis by targeting VDR［J］. Exp Ther Med， 2022， 23（4）：283. doi:10.3892/etm.2022.11213 doi: 10.3892/etm.2022.11213
7	中华医学会糖尿病学分会. 中国2型糖尿病防治指南（2020年版）（上）［J］. 中国实用内科杂志， 2021， 41（8）：668-695.
8	中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南（2017）［J］. 中国骨质疏松杂志， 2019， 29（3）：281-309. doi:10.3969/j.issn.1006-7108.2019.03.001 doi: 10.3969/j.issn.1006-7108.2019.03.001
9	SOBH M M， ABDALBARY M， ELNAGAR S， et al. Secondary osteoporosis and metabolic bone diseases［J］. J Clin Med， 2022， 11（9）：2382. doi:10.3390/jcm11092382 doi: 10.3390/jcm11092382
10	DU Y X， ZHAO Y T， SUN Y X， et al. Acid sphingomyelinase mediates ferroptosis induced by high glucose via autophagic degradation of GPX4 in type 2 diabetic osteoporosis［J］. Mol Med， 2023， 29（1）：125. doi:10.1186/s10020-023-00724-4 doi: 10.1186/s10020-023-00724-4
11	CHEN Y， ZHAO W， HU A， et al. Type 2 diabetic mellitus related osteoporosis： focusing on ferroptosis［J］. J Transl Med， 2024， 22（1）：409. doi:10.1186/s12967-024-05191-x doi: 10.1186/s12967-024-05191-x
12	周影，潘卫民，肖欢，等. 海口地区常住居民老年2型糖尿病患者骨质疏松发生风险列线图预测模型的建立与评估［J］. 中国老年学杂志， 2022， 42（21）：5251-5255.
13	李祥双，谢一帆，段京明. 双能X线检查联合骨代谢指标在糖尿病合并骨质疏松患者中的应用价值［J］. 中国医疗设备， 2023， 38（6）：140-145. doi:10.3969/j.issn.1674-1633.2023.06.025 doi: 10.3969/j.issn.1674-1633.2023.06.025
14	SALAMANNA F， CONTARTESE D， RUFFILLI A， et al. Sharing circulating Micro-RNAs between osteoporosis and sarcopenia： a systematic review［J］. Life （Basel）， 2023， 13（3）：602. doi:10.3390/life13030602 doi: 10.3390/life13030602
15	CIUFFI S， MARINI F， FOSSI C， et al. Circulating MicroRNAs as biomarkers of osteoporosis and fragility fractures［J］. J Clin Endocrinol Metab， 2022， 107（8）：2267-2285. doi:10.1210/clinem/dgac293 doi: 10.1210/clinem/dgac293
16	麦小青，陈邢玉，陈达健，等. 血清miR-23a， miR-30a与2型糖尿病合并骨质疏松的相关性［J］. 解放军医药杂志， 2022， 34（4）：36-39.
17	BEHERA J， ISON J， VOOR M J， et al. Exercise-linked skeletal irisin ameliorates diabetes-associated osteoporosis by inhibiting the oxidative damage-dependent miR-150-FNDC5/pyroptosis axis［J］. Diabetes， 2022， 71（12）：2777-2792. doi:10.2337/db21-0573 doi: 10.2337/db21-0573
18	郭伟壮，兰涛，杨欣建，等. miR-150在骨髓间充质干细胞分化中的作用及其可能的机制［J］. 黑龙江医学， 2019， 43（10）：1143-1146. doi:10.3969/j.issn.1004-5775.2019.10.001 doi: 10.3969/j.issn.1004-5775.2019.10.001
19	QI J L， ZHANG Z D， DONG Z， et al. mir-150-5p inhibits the osteogenic differentiation of bone marrow-derived mesenchymal stem cells by targeting irisin to regulate the p38/MAPK signaling pathway［J］. J Orthop Surg Res， 2024， 19（1）：190. doi:10.1186/s13018-024-04671-6 doi: 10.1186/s13018-024-04671-6
20	WANG F， DENG H， CHEN J， et al. LncRNA MIAT can regulate the proliferation， apoptosis， and osteogenic differentiation of bone marrow-derived mesenchymal stem cells by targeting miR-150-5p［J］. Bioengineered， 2022， 13（3）：6343-6352. doi:10.1080/21655979.2021.2011632 doi: 10.1080/21655979.2021.2011632

组别	例数	miR-23a	miR-150	miR-150-5p
DOP组	52	0.95 ± 0.13	0.63 ± 0.12	0.87 ± 0.13
无DOP组	128	0.57 ± 0.18	0.34 ± 0.07	0.71 ± 0.15
t值		13.820	20.199	6.731
P值		< 0.001	< 0.001	< 0.001

指标	r	95% CI	P值
miR-23a	-0.423	-0.536 ~ -0.295	< 0.001
miR-150	-0.414	-0.528 ~ -0.284	< 0.001
miR-150-5p	-0.279	-0.409 ~ -0.139	< 0.001

自变量	B	SE	Wald χ²	P值	OR	95% CI
年龄	0.534	0.217	6.056	0.014	1.706	1.115 ~ 2.612
BMI	-0.954	0.354	7.263	0.012	0.385	0.192 ~ 0.771
miR-23a	0.746	0.312	5.714	0.017	2.018	1.144 ~ 3.886
miR-150	0.835	0.240	12.059	0.001	2.304	1.438 ~ 3.690
miR-150-5p	1.065	0.352	9.151	0.002	2.902	1.455 ~ 5.786
常数项	-13.166	3.926	11.247	0.001	0.000	-

[1]	Yushi LIU,Qingmei LIN,Man HE,Yang SU,Yin YANG,Hualiang LIN,Zanyi CAI,Xiaoling. GUO. Maternal gestational diabetes， maternal weight gain during pregnancy， and feeding methods on neurodevelopmental delay in their offsprings [J]. The Journal of Practical Medicine, 2024, 40(8): 1108-1113.
[2]	Rui ZHANG,Ying ZHOU,Wenji NI,Ya HUANG,Dandan LI,Tao JIN,Yong. ZHONG. Application value of artificial intelligence⁃basedretinal microvascular analysis in diagnosis of diabetes complications [J]. The Journal of Practical Medicine, 2024, 40(8): 1142-1147.
[3]	Yan LI,Qi WANG,Lu ZHENG,Lihui FENG,Li MA,Jian WEI,Liangshu. LIU. Correlation between IL-17 gene polymorphism and type 2 diabetes mellitus in Han population in southeast Shanxi Province [J]. The Journal of Practical Medicine, 2024, 40(5): 695-701.
[4]	Jianmei SHI,Xixi WANG,Xiaojie WEI. Role of ferritinophagy in the pathogenesis of diabetes and its complications： A review of literature [J]. The Journal of Practical Medicine, 2024, 40(3): 417-422.
[5]	Zhen WANG,Lianjin GUO,Jiarong LIANG,Haoyi YE,Xunmeng. ZHANG. Value of MRI fat quantification parameter combined with 25⁃hydroxyvitamin D in predicting fracture risk in patients with osteoporosis [J]. The Journal of Practical Medicine, 2024, 40(22): 3238-3243.
[6]	Qingmin YANG,Hongxia DING,Xiaoxiao. YE. The interactive effect of vitamin D and triglyceride/high⁃density lipoprotein cholesterol on achieving glycemic control in hospitalized type 2 diabetes patients [J]. The Journal of Practical Medicine, 2024, 40(21): 3054-3060.
[7]	Menglu ZHU,Fengjiao ZHANG,Zhiqiang KANG. Effects of telomere length and plasma AGEs on bone mineral density in type 2 diabetic patients [J]. The Journal of Practical Medicine, 2024, 40(20): 2860-2866.
[8]	Juan TANG,Fen LAN,Linxia MENG,Qinqin ZHANG,Chuanqiang DAI,Zheng LEI,Qilin FANG,Ying LI,Xiaoli WU,Tao. LI. The clinical effect of the whole process blood glucose management on improving postoperative vision in T2DM cataract patients with non-diabetic retinopathy based on visual electrophysiology and OCTA study [J]. The Journal of Practical Medicine, 2024, 40(20): 2888-2899.
[9]	Honglin GU,Xiaoqing ZHENG,Changxiang LIANG,Dan XIAO,Shixing ZENG,Yunbing. CHANG. Surgical strategy and early efficacy of biportal endoscopic transforaminal lumbar interbody fusion for lumbar spondylolisthesis with osteoporosis [J]. The Journal of Practical Medicine, 2024, 40(19): 2696-2702.
[10]	Bin ZHANG,Wei HU,Rongzhen TAN,Panpan YANG,Jun HU,Zhong YUAN,Gongtao. JIANG. Effects of Yishen Huayu Xugu prescription combined with Dixumab on IL-6， β-CTX and bone mineral density in elderly patients operated for osteoporotic lumbar vertebral compression fractures [J]. The Journal of Practical Medicine, 2024, 40(19): 2766-2771.
[11]	Kun WANG,Xiaomei. CAO. A review of studies on chronic obstructive pulmonary disease complicated with osteoporosis [J]. The Journal of Practical Medicine, 2024, 40(19): 2796-2800.
[12]	Chunmei ZHANG,Xinhui HUANG,Jinqiu HU,Xiaoyan BI,Fuli. YA. Sulforaphane protects human platelets from high glucose⁃induced cellular apoptosis through down-regulating PI3K/Akt signaling pathway [J]. The Journal of Practical Medicine, 2024, 40(18): 2530-2536.
[13]	Shuting YANG,Shuoming LUO,Zhiguang. ZHOU. A new vision of diabetes classification： A shift from clinical manifestation to etiological molecular mechanism [J]. The Journal of Practical Medicine, 2024, 40(16): 2199-2205.
[14]	Liehua LIU,Yanbing. LI. Remission of type 2 diabetes： Contending perspectives and practical approaches [J]. The Journal of Practical Medicine, 2024, 40(16): 2206-2210.
[15]	Xin MOU,Chao. LIU. Discussion and reflection on the entry point of traditional Chinese medicine for treatment of diabetes [J]. The Journal of Practical Medicine, 2024, 40(16): 2211-2218.

Correlation between serum levels of miR⁃23a， miR⁃150， and miR⁃150⁃5p and diabetic osteoporosis

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 8

References 20

Related Articles 15

Recommended Articles

Metrics

Comments